Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cathleen Mullarkey Desapio

Endocrinology, Diabetes & Metabolism Princeton, NJ Medical Doctor

NPI 1225073505 CMS profile 146588

419 N Harrison St, Princeton, NJ 08540

Open in the dashboard

General payments

$182,512

730 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cathleen Mullarkey Desapio of Princeton, NJ is reported in the CMS Open Payments database as having received $182,512 across 730 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $654 5
2024 General $2,578 7
2023 General $2,333 9
2022 General $2,332 34
2021 General $33,732 147
2020 General $41,694 173
2019 General $99,189 355

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cathleen Mullarkey Desapio
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Cathleen Mullarkey Desapio were reported at $654. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Cathleen Mullarkey Desapio Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $99,189 $494 $123–$2,253 $163
2020 $41,694 $335 $85–$1,841 $114
2021 $33,732 $398 $88–$1,981 $132
2022 $2,332 $364 $88–$1,568 $149
2023 $2,333 $420 $113–$1,614 $160
2024 $2,578 $440 $121–$1,646 $164
2025 $654 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $68,167 196 payments
  2. Mannkind Corporation $37,521 87 payments
  3. Amarin Pharma Inc. $16,152 63 payments
  4. Janssen Pharmaceuticals, Inc $15,910 60 payments
  5. AbbVie, Inc. $14,506 45 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $13,733 35 payments
  7. Lilly USA, LLC $6,832 29 payments
  8. Medtronic MiniMed, Inc. $2,363 25 payments
  9. Corcept Therapeutics $2,325 13 payments
  10. Abbott Laboratories $962 15 payments
  11. Other $4,042 162 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $139,205 81 payments
  2. Travel and Lodging $16,887 77 payments
  3. Food and Beverage $16,704 562 payments
  4. Consulting Fee $9,645 3 payments
  5. Education $71 7 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $59,686 170 payments
  2. AFREZZA Diabetes Medicine $23,737 56 payments
  3. INVOKANA $15,997 63 payments
  4. Vascepa $15,864 41 payments
  5. AFREZZA Diabetes Medicine $13,784 31 payments
  6. JARDIANCE Diabetes $13,733 35 payments
  7. Synthroid Endocrinology $9,040 21 payments
  8. BYDUREON $7,545 13 payments
  9. JARDIANCE Diabetes $6,687 18 payments
  10. SYNTHROID Immunology $5,433 20 payments
  11. Other $11,709 305 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$23,147

Medicare's payments for the services billed

Medicare patients

63

Average age 74

Services billed

300

39 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 62%
Ischemic heart disease 60%
Arthritis 57%
Heart failure 49%
Atrial fibrillation 46%
Depression 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $2,102
$2,102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

730 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record